Alibaba, WuXi Biologics lead Hong Kong stock rebound on fund inflows, Fed rate focus

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

China Daily Reads

Alibaba, WuXi Biologics lead Hong Kong stock rebound on fund inflows, Fed rate focus

Mainland investors were net buyers of HK$11.6 billion worth of Alibaba shares since it became an eligible component in the Stock Connect scheme this week

This post is for paid subscribers